PetLife
Financiado
INTRODUCTION OF A RANGE OF L CYSTEINE DERIVATIVES AS NUTRITIONAL ADDITIVES IN PE...
INTRODUCTION OF A RANGE OF L CYSTEINE DERIVATIVES AS NUTRITIONAL ADDITIVES IN PET FOOD TO REDUCE OBESITY AND LENGTHEN ANIMAL LIFE
Veterinary research shows that up to 45% of cats and dogs suffer health disorders, with oxidative effects from nutritional
imbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have...
Veterinary research shows that up to 45% of cats and dogs suffer health disorders, with oxidative effects from nutritional
imbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have commercial pet
food exclusively as their source of nutrition and therefore depend on a complete and balanced product for health and
wellbeing.
The PetLife project is based on a promising market and growth opportunity deriving from our current L-Cysteine derivative
product line for use in plant nutrition. This latent cysteine is released into the plant gradually, providing its organism with
several essential health benefits that extend to animals as well. AXEB is set to be the first in Europe and globally to validate
and introduce L-cysteine derivatives as nutritional additives for animals, to solve the problem of providing cysteine without
causing nutritional imbalances and weight gain. The health benefits to be proved in phase 2 validation will convince pet
owners and feed manufacturers of the worth of these new added-value formulations.
Our objective is to take advantage of our know-how in order to broaden the use of this innovative compound as an animal
nutrient and access the EU pet food industry and European pet owners who spend up to €21,000 on each pet over its
lifetime, and €55 per pet every year on veterinary care.
When scaled up to industrial production, the proposed PetLife L-Cysteine derivatives will be commercialized with a target
price 25% cheaper than current pet food additives, and provide more long-ranging health benefits to reduce end user
veterinary expenses.
Although we already possess the knowledge in biotechnology processes for molecule synthesis, we require assistance to
enter the pet food market due to the rigorous regulatory approval process for new additives in the European market. The
possibility of European funding will help us cross the ‘valley of death’ from development to marketplace.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2016-02-27
Fecha Fin: 2016-08-31
Fecha Fin: 2016-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2016-08-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
AXEB BIOTECH
Investigacion, desarrollo, formulacion y comercializacion de materias primas para formulacion de defensivos agricolas, nutricion y farmacia....
Perfil tecnológico
TRL
3-4
80K
Perfil tecnológico
TRL
3-4
80K